As demonstrated by Bi J, et al., fluoxetine use was associated with better prognosis in GBM patients, while citalopram and escitalopram, despite being SSRIs, did not significantly impact overall survival.8 This variability may reflect diverse interactions with cellular pathways in glioma cells; for example, fluoxetine inhibits oncogenic EGFR signaling more effectively than other SSRIs.8 This also explains why there was so much heterogeneity in the conclusions of the 7 included studies. Here, EGFR is linked to glioblastoma.